Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ: MLTX )

40.83 -0.09 (-0.22%)
Streaming Delayed Price Updated: 2:23 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >
Insiders Promise Not to Sell AMTD Digital (HKD) Stock Until 2025
AMTD Digital (HKD) stock is on the move Monday after insiders promised not to sell shares on the public market for a few more years. 
Via InvestorPlace
Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Is FibroGen (FGEN) Stock Down 81% Today?
FibroGen (FGEN) stock is heading lower on Monday after the company's Phase 3 clinical trial failed to meet its primary endpoint. 
Via InvestorPlace
US Stocks Edge Higher; Goldman Sachs Downgrades Tesla To Neutral
U.S. stocks traded slightly higher this morning, with the Dow Jones gaining around 25 points on Monday. Following the market opening Monday, the Dow traded up 0.08% to 33,753.64 while the NASDAQ rose... 
Via Benzinga
The Latest Analyst Ratings for MoonLake
Via Benzinga
What 10 Analyst Ratings Have To Say About MoonLake
Via Benzinga
Where MoonLake Stands With Analysts
Via Benzinga
Why Is MoonLake Immunotherapeutics (MLTX) Stock Up 93% Today?
MoonLake Immunotherapeutics (MLTX) stock is taking off on Monday after reporting positive results from a Phase 2 clinical trial. 
Via InvestorPlace
Why Mutual Fund Darling And Top 1% Stock MoonLake Immunotherapeutics Nearly Doubled
The company is treating a painful skin condition and could go up against AbbVie. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Lucid Stock Moved Into the Fast Lane, but This Nasdaq Biotech Was Monday's Big Winner
Markets looked poised to start the new week flat. 
Via The Motley Fool
Why MoonLake Immunotherapeutics Stock Is Shooting Higher Today
MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its Phase 2 MIRA trial evaluating the Nanobody sonelokimab in patients with moderate-to-severe 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
10 Short Squeeze Stocks To Watch: Getty Images, Intuitive Machines, Wearable Devices & More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
10 Short Squeeze Stocks To Watch: AirSculpt, Arrival, Toro, Groupon, Beam Global And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
10 Short Squeeze Stocks To Watch: Toro Corp, Greenidge Generation, Getty Images And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
10 Short Squeeze Stocks To Watch: Toro Corp, PaxMedica, Getty Images And More
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High-short interest and high-cost to borrow are among the... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
10 Short Squeeze Stocks To Watch: Getty Images, Guardforce AI And 2 Stocks Moving Up Over 1,000 Positions On The Leaderboard
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the... 
Via Benzinga
10 Short Squeeze Candidates: Getty Images Tops List, PaxMedica Rejoins Top Five, MicroStrategy Moves Up And More
Potential short squeeze plays gained steam in 2021 and continued through 2023 with new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on... 
Via Benzinga
10 Short Squeeze Candidates: PaxMedica, Blue Apron, MicroStrategy And More
Potential short squeeze plays gained steam in 2021 and continued through 2022 with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
10 Short Squeeze Candidates: China Jo-Jo Drugstores, Expion360, MoonLake, Silvergate And More
Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common traits... 
Via Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.